Ethic Inc. Takes $241,000 Position in Ultragenyx Pharmaceutical Inc. $RARE

Ethic Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,603 shares of the biopharmaceutical company’s stock, valued at approximately $241,000.

Several other institutional investors and hedge funds have also recently modified their holdings of RARE. GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares during the period. WCM Investment Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 49.1% during the 1st quarter. WCM Investment Management LLC now owns 202,213 shares of the biopharmaceutical company’s stock valued at $7,648,000 after purchasing an additional 66,604 shares during the period. GF Fund Management CO. LTD. raised its position in shares of Ultragenyx Pharmaceutical by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,364 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 425 shares during the period. Xponance Inc. raised its position in shares of Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company’s stock valued at $455,000 after purchasing an additional 347 shares during the period. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of Ultragenyx Pharmaceutical by 5.1% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 340,975 shares of the biopharmaceutical company’s stock valued at $12,347,000 after purchasing an additional 16,538 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at $3,095,132.77. This trade represents a 7.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,456 shares of company stock valued at $328,486 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 1.7%

Shares of NASDAQ:RARE opened at $35.17 on Friday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $53.47. The stock has a market capitalization of $3.39 billion, a P/E ratio of -6.36 and a beta of 0.21. The firm has a fifty day simple moving average of $31.17 and a two-hundred day simple moving average of $32.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The business had revenue of $166.50 million during the quarter, compared to analysts’ expectations of $161.37 million. During the same period last year, the company posted ($1.52) EPS. The business’s revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on RARE shares. Morgan Stanley cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Canaccord Genuity Group cut their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, July 14th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Finally, Wells Fargo & Company started coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They set an “overweight” rating and a $65.00 target price for the company. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $82.27.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.